9Suppliers
0Customers
3Debt Items
0Related Chains

Immunic, Inc. Suppliers

TickerNameConfidenceEvidence
B-RILEY-SECURITIES B-RILEY-SECURITIES 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
BROOKLINE-CAPITAL-MARKETS BROOKLINE-CAPITAL-MARKETS 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
DAIICHI-SANKYO-CO-LTD DAIICHI-SANKYO-CO-LTD 90% During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit.
GUGGENHEIM-SECURITIES GUGGENHEIM-SECURITIES 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
LIFESCI-CAPITAL LIFESCI-CAPITAL 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
STIFEL STIFEL 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
WILLIAM-BLAIR WILLIAM-BLAIR 90% Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents…
BVF-PARTNERS-L-P BVF-PARTNERS-L-P 80% On February 12, 2026, the Company entered into a purchase and sale agreement (the "Royalty Purchase Agreement") with certain Series B Warrant holders who had purchased a predetermined number of Serie…

Immunic, Inc. Customers

No clients on recordNo downstream customers found in our database for Immunic, Inc..

Immunic, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IMUX-DEBT Debt stack $146,000 90% Market cache reports total debt of $146,000.
IMUX-DEBT-10256 Warrants outstanding: 3719.6 90% xbrl warrant detail from xbrl 2024-12-31.
IMUX-DEBT-10257 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-12-31.

Immunic, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Immunic, Inc..

Immunic, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Immunic, Inc..

Immunic, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.